key: cord-0737095-j69vz03r authors: Dolan, Susan A.; Mulcahy Levy, Jean; Moss, Angela; Pearce, Kelly; Butler, Molly; Jung, Sarah; Dominguez, Samuel R.; Mwangi, Eric; Maloney, Kelly; Rao, Suchitra title: SARS‐CoV‐2 persistence in immunocompromised children date: 2021-08-28 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.29277 sha: 3615ac6cd770c3d2c95afb846286fc2d2a9ad815 doc_id: 737095 cord_uid: j69vz03r OBJECTIVES: We evaluated the length of time immunocompromised children (ICC) remain positive for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), identified factors associated with viral persistence, and determined cycle threshold (C (T)) values of children with viral persistence as a surrogate of viral load. METHODS: We conducted a retrospective cohort study of ICC at a pediatric hospital from March 2020 to March 2021. Immunocompromised status was defined as primary, secondary, or acquired due to medical comorbidities/immunosuppressive treatment. The primary outcome was time to first of two consecutive negative SARS‐CoV‐2 polymerase chain reaction (PCR) tests at least 24 hours apart. Testing of sequential clinical specimens from the same subject was conducted using the Centers for Disease Control (CDC) 2019‐nCoV real‐time reverse transcriptase (RT)‐PCR Diagnostic Panel assay. Descriptive statistics, Kaplan–Meier curve median event times and log‐rank tests were used to compare outcomes between groups. RESULTS: Ninety‐one children met inclusion criteria. Median age was 15.5 years (interquartile range [IQR] 8–18), 64% were male, 58% were White, and 43% were Hispanic/Latinx. Most (67%) were tested in outpatient settings and 58% were asymptomatic. The median time to two negative tests was 42 days (IQR 25.0–55.0), with no differences in median time by illness presentation or level of immunosuppression. Seven children had more than one sample available for repeat testing, and five of seven (71%) children had initial C (T) values of <30 (moderate to high viral load); four children had C (T) values of <30, 3–4 weeks later, suggesting persistent moderate to high viral loads. CONCLUSIONS: Most ICC with SARS‐CoV‐2 infection had mild disease, with prolonged viral persistence >6 weeks and moderate to high viral load. The coronavirus disease 2019 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be an ongoing global health crisis. SARS-CoV-2 causes mild to moderate upper respiratory tract infection in most children, but the true burden of disease is unknown due to asymptomatic infection. Viral load typically peaks with symptom onset and falls to undetectable levels by the third week, when patients generally begin to develop antibodies. 1 Patients with a suppressed immune system, such as those being treated for cancer, are susceptible to more severe viral infections. 2 While these infections, including SARS-CoV-2, have the potential to be more severe in immunocompromised adults, 3, 4 emerging data suggests that SARS-CoV-2 does not necessarily present with an increased risk of severe disease in immunocompromised children (ICC). [5] [6] [7] [8] However, the persistence of SARS-CoV-2 infection in pediatric immunosuppressed patients is still unknown, with case series suggesting that infection can be more prolonged in this population. 9 An understanding of viral persistence in immunocompromised hosts has important public health implications. Specific impacts include the effective prevention of disease transmission through infection control practices, as well as decreasing the risk of emerging variants given the concern that SARS-CoV-2 variants may have emerged from prolonged replication within immunocompromised hosts. 10, 11 The objectives of our study were to determine the length of time that ICC are positive for SARS-CoV-2; identify the sociodemographic and clinical factors associated with prolonged viral shedding; and determine the cycle threshold (C T ) values of a subset of patients with viral persistence as a surrogate of viral load and potential transmissibility. We conducted a retrospective cohort study of children evaluated for SARS-CoV-2 at Children's Hospital Colorado (CHCO) from March 19, 2020 to March 28, 2021. We included children who were positive for SARS-CoV-2 by polymerase chain reaction (PCR) and were concurrently confirmed as immunocompromised by study investigators via chart review. CHCO is a regional, academic quaternary care pediatric hospital with affiliated sites serving children in the Denver metropolitan area, the We included symptomatic and asymptomatic children in both inpa- Nasopharyngeal swabs, nasal aspirates, tracheal aspirates, and bron- Testing was completed per manufacturer instructions as outlined in the respective emergency use authorization instructions for use. [12] [13] [14] [15] Residual specimens from a subset of study subjects with persistently positive SARS-CoV-2 were retested using the CDC 2019-nCoV realtime RT-PCR Diagnostic Panel. Reported C T values were calculated by taking the mean of the C T values for the N1 and N2 viral gene targets. For samples in which SARS-CoV-2 was not detected, a C T value of 40 was assigned. We defined low ANC or ALC as a level <1000 cells/µl, and moderately low ANC or ALC as a level of 1000-1500 cells/µl. The primary outcome was time in days to the first of two consecutively negative tests. Secondary outcomes included time to the first negative test, hospitalization related to SARS-CoV-2 infection, and C T values from PCR assays. For all study objectives, unless otherwise specified, we summarized data descriptively using frequencies for categorical variables and mea- The We compared characteristics of children with a first negative test within 30 days of their initial SARS-CoV-2 diagnosis with that of chil- Plot of C T values from SARS-CoV-2 PCR testing over time among children with sequential samples available for retesting (n = 7). Legend: Plot of mean C T values (y-axis) from SARS-CoV-2 PCR testing on the CDC assay over time (x-axis) in days from initial positive test. Repeated testing that yielded a negative result on the CDC assay or intermittent negative results on clinical testing represented as C T value of 40. Each line represents a unique patient. Clinical information regarding each patient is shown in accompanying Table S3 dren with a first negative test after 30 days ( Table 2 ). Children who took >30 days for their SARS-CoV-2 tests to turn negative were more likely to be receiving chemotherapy and steroids, but these findings were not statistically significant. In our cohort, of the 30 children who were hos- In our study evaluating SARS-CoV-2 viral persistence in ICC, we found that the median time to the first of two negative tests was 6 weeks. Most children had an oncologic diagnosis, were tested in outpatient settings prior to admission or for procedural sedation, and over half of those tested were asymptomatic at the time of their first positive test. There was no significant difference in time to negativity among symptomatic versus asymptomatic children. Among children who remained positive at day 30, half had C T values <30, suggesting persistence of moderate to high viral loads and assumed potential risk of transmission. Our study highlights the importance of PCR-based screening for ICC to guide isolation duration, irrespective of symptom presentation. These data support our current practice, with the need for at least two negative tests prior to isolation removal, given the potential for intermittent negative followed by positive results, and risk for ongoing, potential transmission even several weeks from initial infection. The CDC recommends an isolation period of 10 days in healthy, immunocompromising conditions, which we hypothesize is due to this population having the highest impairment of adaptive immunity. These children also represent the population of children with the greatest degree of lymphopenia, which has been shown in adults to be associated with more severe disease. 18 Another study has also shown that patients critically ill from SARS-CoV-2 were more likely to have a decrease in CD3+CD4+ T cells compared to noncritical patients. 19 Additionally, a study of adult cancer patients found a general lack of Tcell response to the N, M, and S proteins from SARS-CoV-2. While these findings suggested lack of a protective T-cell response, the patients presented with mild illnesses despite relatively high viral loads. 12 And although we had one death in our patient cohort post bone marrow transplant, allogeneic, autologous and CAR-T therapy patients have overall favorable outcomes following SARS-CoV-2 infection. 13 Similar to findings from adult studies, we did not see a relationship between clinical presentation and persistent positive SARS-CoV-2 status. An adult study of 3758 adults retested following initial SARS- 20 These data further support the need for extended isolation duration for ICC given the persistence of relatively low C T values, suggesting potentially transmissible virus. Low CT values indicating relatively high viral loads were observed even in asymptomatic ICC, reflecting a need for test-based isolation protocols, rather than symptom-based isolation. There are several limitations of this single-center, retrospective study. A small sample size precluded adjusted analyses to account for factors that may influence viral persistence and increased the risk of a type II error. Given the retrospective nature of the study, there was nonstandardized repeat testing, and the frequency and intervals were not consistent between study participants. Repeat testing at our institution was recommended at 3 weeks from the first positive test, which may have increased our median time to negative testing, but most children in our cohort were still positive at this timepoint. We did not have a cohort of non-ICC with repeat SARS-CoV-2 testing, so we were not able to compare the degree of viral persistence in ICC with a healthy population. Finally, clinical SARS -CoV-2 testing was conducted on different testing platforms, and there were a limited number of remaining sequential samples available for repeat testing to yield C T data. In conclusion, our study demonstrates prolonged viral persistence of SARS-CoV-2 viral material in ICC, even in asymptomatic children, with moderate to high viral loads seen in the majority of children several weeks from initial positive testing. These findings highlight the importance of PCR-based screening for ICC to help guide isolation duration, irrespective of symptom presentation, given the risk for ongoing transmission even several weeks from initial infection. We would like to acknowledge the Clinical Microbiology Laboratory at Children's Hospital Colorado for their tireless work during the pandemic. Suchitra Rao and Samuel R. Dominguez received research support from BioFire Diagnostics. The remaining authors have no conflict of interest to disclose. The data that support the findings of this study are available from the corresponding author upon reasonable request. Jean Mulcahy Levy https://orcid.org/0000-0002-3022-4246 Suchitra Rao https://orcid.org/0000-0002-0334-6301 Interpreting diagnostic tests for SARS-CoV-2 Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak Severity of COVID-19 in children with cancer: report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project Clinical characteristics and outcome of severe acute respiratory syndrome coronavirus 2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica Screening of COVID-19 in outpatient children with cancer or solid organ transplantation: preliminary report COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients Clinical course of COVID-19 among immunocompromised children: a clinical case series SARS-CoV-2 one year on: evidence for ongoing viral adaptation SARS-CoV-2 evolution during treatment of chronic infection Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation Xpert Xpress SARS-CoV-2/Flu/RSV: Instructions for use. U.S. Food and Drug Administration. 2020. Accessed BioFire Respiratory Panel 2.1 (RP2.1): Instructions for use. U.S. Food and Drug Administration. 2020. Accessed Accessed SARS-CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with mild coronavirus disease Time to SARS-CoV-2 PCR clearance in immunocompromising conditions: is test-based removal from isolation necessary in severely immunocompromised individuals? Open Forum Infect Dis Clinical course and risk factors of disease deterioration in critically ill patients with COVID-19 CD4 and CD8 lymphocyte counts as surrogate early markers for progression in SARS-CoV-2 pneumonia: a prospective study Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series Additional supporting information may be found online in the Supporting Information section at the end of the article.